EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease

Nicole M. Garcia, Uma Mahadevan, Sara Lewin, Rishika Chugh

JCC Plus · 2026-05 · 1 (3)

DOI: 10.1002/jcc5.70040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCC Plus, online erschienen am 21.05.2026. Verfasst von Nicole M. Garcia und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Upadacitinib is a selective Janus kinase 1 inhibitor that has demonstrated rapid onset and efficacy in patients with moderate‐to‐severe Crohn's disease (CD) and ulcerative colitis (UC). Here, we describe the real‐world efficacy and safety of upadacitinib in combination with biologic therapies for IBD.

Methods

We performed a single center retrospective study of patients with moderate‐to‐severe IBD on upadacitinib in combination with biologic therapy from August 2020 to August 2024. The primary outcome was clinical response and remission at weeks 8, 28, and 52. Secondary outcomes include endoscopic response and remission, intestinal ultrasound response, and biomarker response. Adverse events (AEs) through week 52 were recorded.

Results

Thirty‐seven patients (10 UC and 27 CD) were included. All patients were anti‐TNF exposed, 34 (91.8%) had previously received > 2 biologic therapies and 8 (21.6%) had received dual advanced therapy. Upadacitinib was administered alongside vedolizumab ( n = 13, 35.1%); ustekinumab ( n = 14, 37.8%); risankizumab ( n = 9, 24.3%); infliximab ( n = 1, 2.7%); and golimumab ( n = 1, 2.7%). Median duration of combination therapy was 365 days (IQR 294,365). At weeks 8, 28, and 52, 12/17 (70.6%), 16/26 (61.5%), and 20/23 (87.0%) achieved clinical response and 6/17 (35.3%), 13/26 (50.0%), and 14/23 (60.9%) achieved clinical remission, respectively. Eighteen patients (48.6%) experienced AEs, and four patients (10.8%) had a serious AE requiring hospitalization.

Conclusions

In patients with highly refractory IBD, upadacitinib in combination with another biologic therapy can be effective with 60% achieving clinical remission at 52 weeks. Additional studies are needed to further assess the safety of upadacitinib combination therapy.

Zitieren

APA

Garcia, N. M., Mahadevan, U., Lewin, S., & Chugh, R. (2026). Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease. JCC Plus, 1(3). https://doi.org/10.1002/jcc5.70040

Vancouver

Garcia NM, Mahadevan U, Lewin S, Chugh R. Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease. JCC Plus. 2026;1(3). doi:10.1002/jcc5.70040

BibTeX
@article{Garcia2026,
  author = {Garcia, Nicole M. and Mahadevan, Uma and Lewin, Sara and Chugh, Rishika},
  title = {Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease},
  journal = {JCC Plus},
  year = {2026},
  volume = {1},
  number = {3},
  doi = {10.1002/jcc5.70040}
}
Kostenlos starten →